Project introduction and objectives

Due to the aging population, cancer is emerging as a major global burden. Indeed, cancer is now the number one cause of death in the Netherlands, with 100,000 new cases diagnosed and more than 40,000 deaths annually. Current drug treatment of metastatic cancer is ineffective: only one in four patients derives benefit from anti-cancer drugs. The last two to three decades has taught us that cancer results from multiple genetic defects and that such defects are often dissimilar in individuals suffering from the same type of cancer. While this explains the heterogeneous response to anti-cancer agents of patients suffering from apparently similar cancers, it provides at the same time a huge obstacle for the effective treatment of cancer.

In recent years, treatment of cancer has been shifting from a “one size fits all” approach to a more personalized approach, in which the patient is treated according to the specific defects present in the individual tumor. This transition is enabled by two major developments: first, the ability to rapidly sequence the DNA of cancers at low cost, which is starting to generate inventories of genetic defects in individual cancers; and second, the development of highly selective cancer therapeutics, which act on the products of the genes that are mutated in cancer. These 'magic bullets' provide targeted treatment options for patients with a defined genotype. However, despite this progress, intrinsic heterogeneity of the tumor and tumor plasticity frequently and rapidly results in resistance to the applied drugs.

The mission of the consortium is to determine and understand genetic alterations in individual tumors in order to deliver precision medicine to individual cancer patients.

Our ambition is to significantly improve life expectancy and quality of life for cancer patients and to provide multidisciplinary training for the next generation of cancer researchers and specialists. brings together prominent cancer research groups from seven research institutions in the Netherlands. The scientists were selected on the basis of their excellence and their commitment to the mission of the program. A number of participants have been long-standing collaborators, in particular through the Cancer Genomics Center (CGC) that was supported by the Netherlands Genomics Initiative (NGI) from 2002 until 2012.

In the program, we combine the expertise, knowledge and infrastructure of internationally established as well as junior basic scientists and clinicians from seven research institutions in the Netherlands to

1) understand how specific genetic changes in individual tumors determine tumor behavior, including their responses to cancer drugs, and

2) bring this new knowledge into the clinic.


28 Aug 2017

Amgen Foundation launches Amgen Biotech Experience in the Netherlands

In the next three years, the DNA Labs on the Road will collaborate with the Amgen Biotech Experience to educate Dutch high school students about biotechnology.

Read more >

16 Jun 2017

CGC members awarded Spinoza Prize

We proudly congratulate our CGC members Alexander van Oudenaarden and Albert Heck for being awarded the Spinoza Prize. Albert Heck, isprofessor in the field of mass spectrometryand proteomics. Alexander van Oudenaarden is professor of quantitative biology of gene regulation and director of the Hubrecht Institute. 

Read more >

18 Nov 2016

Gogola wins CGC poster award

On November 18th, Ewa Gogola (NKI) was awarded with the CGC poster award 2016. Eva received the award during the KIT meeting on Genomic Instability in Cancer for her poster entitled 'Loss of PARG causes PARP inhibitor resistance in BRCA2-deficient mouse mammary tumors'.

Read more >

More News >


16 & 17 Nov 2017

CGC annual meeting New Horizons in Cancer Research

On 16-17 November 2017, CGC will host its annual meeting entitled 'New Horizons in Cancer Research'. Attendance is free of charge however. Registration is closed.  Location: Koninklijk Instituut voor de Tropen, Mauritskade 63 Amsterdam.  

Read more >

29 Sep 2017

CGC PI meeting

This year 10 new PI's joined the CGC consortium. During the meeting on September 29 they will present their work and expertise. 

Read more >

31 May - 02 Jun 2017

Workshop: Functional Analysis of Sequence Variants in Hereditary Breast- and Ovarian Cancer Genes

Improving Genetic Counseling and Cancer Treatment Strategies

Read more >

More Events >